| 1. |
|
|
| 2. |
|
|
| 3. |
- Bergman, Annika, et al.
(författare)
-
Sjukvård och samhälle får betala högt pris för rotavirusinfektioner hos barn : Svensk deskriptiv kostnadsstudieger prisuppgifter
- 2008
-
Ingår i: Läkartidningen. - Stockholm : Sveriges läkarförbund. - 0023-7205 .- 1652-7518. ; 105:16, s. 1186-1191
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Rotavirus gastroenterit is the most frequent cause of severe diarrhoea in children <5 years of age. Morbidity and resource use due to rotavirus are substantial, though comprehensive data on the economic impact of the disease in Sweden are lacking. The objective of this study was to estimate the average cost per episode of confirmed rotavirus gastroenteritis in primary care, emergency department and hospital settings in Sweden. The total societal cost (including direct medical, direct nonmedical and indirect cost) per episode was estimated to SEK4307 in the primary care setting, SEK5837 in the emergency department setting and to SEK19 456 in the hospital setting. Loss of productivity due to work absenteeism among parents was one of the major costs from a societal perspective. The result shows that rotavirus incurs considerable resource utilisation in all health care settings and substantial costs for the health care sector and the society.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Carlsson, Rose-Marie, et al.
(författare)
-
[Time for booster doses against whooping cough for 10-year-old children]
- 2005
-
Ingår i: Lakartidningen. - 0023-7205. ; 102:35, s. 2394-8
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Acellular pertussis vaccine was introduced in Sweden in 1996 at the age of 3, 5 and 12 months, after a 17 year period without general vaccination against pertussis. At present, the incidence of notified pertussis has decreased to 1/10 of what was seen 10 years ago. In spite of the dramatic decrease, the disease is not eliminated. In accordance with the experience of other countries, most cases in Sweden are reported among older children and adults, while the highest risk of severe disease is still seen in infants. Many industrialized countries have introduced booster dose(s) in order to control the spread of pertussis. The Swedish National Board of Health and Welfare has recently initiated a major revision of the vaccines used and the schedule of the national vaccination program. Until the final proposal and in order not to miss the opportunity to boost pertussis immunity in children who were vaccinated as infants at the reintroduction of pertussis vaccination, the Board now recommends the Swedish municipalities as an interim measure to include pertussis in the current school booster against diphtheria and tetanus at 10 years of age with a full dose vaccine.
|
|
| 8. |
- Carlsson, Rose-Marie, et al.
(författare)
-
Vaccinscheman inom EU behöver göras mer lika : More equal vaccination schedules in the European Union needed
- 2008
-
Ingår i: Läkartidningen. - Stockholm : Sveriges läkarförbund. - 0023-7205 .- 1652-7518. ; 105:22, s. 1665-1669
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- The worldwide variation in vaccination schedules often induces questions about complementary vaccinations to children in migrating families. Also the European vaccination programmes seem to differ widely, but there are in fact many similarities. A two or three-dose priming schedule, with 1, 1 ? or 2 months interval within the three-dose schedule, is used for immunisation against diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b and in many countries also against hepatitis B. In some countries hepatitis B vaccination is started at birth. An early booster at 10-24 months is also generally implemented, with very few exceptions. At least one additional booster dose against diphtheria and tetanus is recommended within the age intervals 4-7 or 11-18 years of age. Most countries also have scheduled boosters against polio and pertussis within these intervals. Nowadays all countries offer two doses of MMR. The first dose is usually given at 12-18 months of age, while there is a wide age range for the second dose. A majority of countries give the second MMR at 3-9 years of age, five countries at 13-24 months whereas nine countries vaccinate at 9-13 years of age.
|
|
| 9. |
- Carlsson, Rose-Marie, et al.
(författare)
-
[Whooping cough is life-threatening for small children. Generous prophylaxis and contact tracing reduce the risks]
- 2005
-
Ingår i: Lakartidningen. - 0023-7205. ; 102:35, s. 2390-2
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- The article presents clinical features of pertussis in older children and adults as well as in unvaccinated infants, with the aim to increase the awareness of the disease and to promote implementation of chemoprophylaxis in households with infants. The national routines for reporting according to the Communicable Diseases Act are outlined, contact-tracing around cases of pertussis being mandatory since July 2004.
|
|
| 10. |
|
|
